fbpx Skip to main content

BioCommunique Article

Bringing you the latest financial and strategic news in life science. Sign up for Biocom California’s newsletter to receive news straight to your inbox.

Adamas receives FDA approval for Parkinson’s drug, Jazz acquires GW Pharma, ViaCyte names Michael Yang as new President & CEO

  • 2021-02-04T20:00:00.000+0000
  • California
  • Author: Lauren Panetta

Adamas Pharmaceuticals received FDA approval for Second Indication for GOCOVRI®, the first approved medication to treat OFF and dyskinesia motor complications in Parkinson’s patients.

Hologic and Google Cloud will collaborate to advance next-generation digital diagnostic capabilities and catalyze new discoveries in cervical cancer per their new agreement.

Jazz Pharma will acquire GW Pharma, maker of the first FDA-approved prescription cannabinoid drug, used to treat epilepsy, in a cash-and-stock deal worth $7.2B.

Gilead is partnering with Gritstone Oncology for their latest play to help develop an HIV-specific therapeutic vaccine in a $60 million upfront deal with up to $785M in options.

Horizon Therapeutics has acquired AstraZeneca spinout Viela Bio for $3B, adding a host of early-stage candidates, R&D capabilities, and an approved antibody to its pipeline.

Illumina is partnering with Sequoia Capital to launch a genomics incubator in China.

Cytiva acquired Canadian aseptic filling innovator Vanrx Pharmasystems in a play to advance personalized medicine innovation.

Encodia closed their $75M Series C Financing led by Northpond Ventures and Deerfield Management.

Salk’s NOMIS Center received $9.5M from the NOMIS foundation to continue Salk’s legacy of advancing and improving human health and immunity.

ViaCyte appointed Michael Yang as President & CEO and shared an update on their expansion of manufacturing capacity to support therapeutic research.

Merck will collaborate with Artiva in a milestone-heavy deal focused on Artiva’s CAR-NK cell manufacturing platform.

MAIA Biotechnology entered a clinical supply agreement with Regeneron to evaluate a novel administration of non-small cell lung cancer drug Libtayo®.